Conference Compendium: The Top 10 Takeaways From ESMO 2024
ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.
Lenvatinib Combo Yields Substantial Antitumor Activity in Endometrial Cancer
Deep and durable responses were observed with lenvatinib plus pembrolizumab in patients with stage III/IV recurrent endometrial carcinoma.
1-Year Trastuzumab Regimen Yields DFS in ERBB2+ Breast Cancer
DFS was improved with 1-year trastuzumab in patients with ERBB2-positive breast cancer enrolled in the SOLD trial.
FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma
Data from the KEYNOTE-483 trial support the FDA approval of the pembrolizumab-based combination in this pleural mesothelioma population.
Tremelimumab Combo Improves OS Vs Sorafenib in Unresectable Liver Cancer
Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.
Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast Cancer
Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.
HER3-DXd Significantly Improves PFS Vs Chemo in Advanced EGFR+ NSCLC
HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.
Survival Improves With Atezolizumab Switch Therapy in BRAF+ Melanoma
Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.
Neoadjuvant TAR-200 Combo Shows Responses in Muscle-Invasive Bladder Cancer
Data from the SunRISe-4 trial demonstrate the benefit of adding TAR-200 to checkpoint inhibition among patients with muscle-invasive bladder cancer.
Non-Operative Management Does Not Compromise DRFS in pMMR Rectal Cancer
NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.
Ribociclib Combo Yields Extended iDFS Benefit in HR+/HER2– Breast Cancer
Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.
Breastfeeding Is Feasible Amid Endocrine Therapy Break in HR+ Breast Cancer
Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.
Single-Fraction Radiotherapy Improves Pain in Hepatic Cancer
Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.
Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs
Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.
Neoadjuvant Durvalumab/Chemo, Adjuvant Durvalumab Improves EFS in Cisplatin-Eligible MIBC
Thomas Powles, MBBS, MRCP, MD, presented results from the NIAGRA trial assessing perioperative durvalumab in patients with cisplatin-eligible MIBC.
QOL, Pain Deterioration Improve With T-DXd in HER2-Low Breast Cancer
QOL data from DESTINY-Breast06 support T-DXd as a new therapeutic option in previously treated HER2-low and HER2-ultralow metastatic breast cancer.
CheckMate 77T Highlights EFS Benefit in Perioperative Nivolumab in Resectable NSCLC
A median EFS of 40.1 months was noted in patients resectable NSCLC given perioperative nivolumab vs placebo.
Hypofractionated Radiation Noninferior to Normofractionated Radiation in Early Breast Cancer
In patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.
Ramucirumab Combo Shows No Significant OS Improvement in Metastatic CRC
Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.
OS Increase Observed in Neoadjuvant Pembrolizumab Combo Plus Adjuvant Therapy in Early TNBC
A pembrolizumab regimen for patients with early-stage triple-negative breast cancer yielded improved overall survival.
Pembrolizumab Combo Shows DFS Benefit in dMMR Endometrial Cancer Subgroup
The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.
Superiority Noted in Adagrasib Vs Docetaxel in Patients With KRAS G12C-Mutated NSCLC
Superior efficacy outcomes were noted when adagrasib was used to treat patients with KRAS G12C NSCLC and among those with brain metastases.
rPFS/OS Benefit in Radium-223 Plus Enzalutamide in mCRPC
Significant survival benefits were observed with Radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Retifanlimab Plus Carboplatin Meets PFS End Point in Metastatic SCAC
The primary end point of progression-free survival was met with retifanlimab to carboplatin and paclitaxel in patients with metastatic SCAC.
Clinical Benefit Improves With Relatlimab Combo in Recurrent NSCLC
The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.
Pembrolizumab/CRT Improve Survival in High-Risk Locally Advanced Cervical Cancer
Pembrolizumab combination improved efficacy outcomes vs chemoradiotherapy alone in patients with advanced cervical cancer.
Neoadjuvant ET And De-Escalated Chemotherapy Lead to ‘Exceptionally Excellent’ Survival in HR+/HER+ Early Breast Cancer
Neoadjuvant endocrine therapy or paclitaxel with trastuzumab/pertuzumab elicited significant survival in HR-positive, HER2-positive early breast cancer.
TILs May Play Prognostic Role in Overall Survival in Trastuzumab Treatment of Early HER2-Positive Breast Cancer
High TILs may predict who may have a reduced risk for disease relapse or death in patients with early HER2-positive breast cancer treated with trastuzumab.
Amivantamab/Chemo Shows Sustained OS in Advanced EGFR+ NSCLC
Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.
Belrestotug/Dostarlimab Improves ORR in PD-L1–High NSCLC
Data from the GALAXIES-Lung 201 trial found efficacy improvement in patients with advanced NSCLC.
